In the first nine months, Krka Group sold goods and services in the amount of 971.9 million Euros, which is five percent more than in the same period last year. Kroc said it was the largest nine-month sale. Net profit reached 120.8 million euros in the first nine months of the year and was 10% higher than in the previous year.
Up to 93% of revenues, i.e. EUR 903.4 million, Krka reached foreign markets in the first nine months. Among them, the largest sales region is Eastern Europe with a share of 29.6%. By the end of September, Krk's profit was 287.6 million Euros, which is six percent more than in the first nine months of last year. In Russia, the largest single market for Krk, sales rose two percent to 189.3 million euros.
The second in terms of sales was the region of Central Europe with sales of 239.6 million Euros, which is six percent more than in the same period last year. Sales grew in Poland, the largest market in this region, as well as in other places, with the exception of Latvia.
In Western Europe, most were sold in Germany
In the region of Western Europe, sales for the nine months decreased by 3 percent to 211 million euros, while the Krka group mainly sold in Germany, and then the Scandinavian countries, Spain, France and Italy.
In South-Eastern Europe, where Romania and Croatia are the main markets of Krka, the group managed to increase sales by 14 percent to 132.3 million euros.
Sales in the Slovenian market accounted for 7.1% of the total sales of the Krka Group, which is 68.6 million Euros, three percent more than a year ago.
Total sales increased in all product groups and services. Among them, sales of prescription drugs, which account for more than four-fifths of the Group’s total sales, increased by 5% to 804.3 million Euros.
All estimated business indicators in the first nine months of 2018 are better than in the same period last year, they can still be found in Krk. The operating profit of Krk in the amount of 163.8 million Euros was 10% higher than in the comparable period last year, as well as the net profit of 120.8 million Euros.
In the first nine months of the year, Krka registered 16 new products in 36 pharmaceutical forms and strengths, and 66 million euros were invested for investments in this period. At the end of September there were 11,226 employees in the Krka group, which is four percent more than nine months ago.